Dendritic Cell News and Research

Latest Dendritic Cell News and Research

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have discovered a way to amp up the power of killer T-cells, called CD8 cells, making them more functional for longer periods of time and boosting their ability to multiply and expand within the body to fight melanoma, a new study has found.

11 May 2011

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced updated long-term data from a Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme, the most common and aggressive form of brain cancer.

6 May 2011

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

Northwest Biotherapeutics today announced that four medical centers across the country are actively recruiting and screening to enroll additional new patients in the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal type of brain cancer.

4 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

ARIAD Pharmaceuticals, Inc. today announced execution of three exclusive out-license agreements for separate aspects of its ARGENT™ cell-signaling regulation technology.

20 Apr 2011

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

ImmunoCellular Therapeutics, Ltd., announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme presented safety and preliminary efficacy data yesterday at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

A novel brain tumor vaccine clinical trial study demonstrates a longer survival time in patients with glioblastoma, according to findings being presented at the 79th Annual Scientific Meeting of the American Association of Neurological Surgeons in Denver.

12 Apr 2011

Research outlines how cilia disease gene products regulate early cilium formation

An international collaboration jointly led by University College Dublin, University of Alabama and Simon Fraser University, British Columbia has outlined in the Journal of Cell Biology how cilia disease gene products regulate important aspects of early cilium formation and the integrity of the ciliary transport gate.

21 Mar 2011

Drug delivery breakthrough for Alzheimer’s disease

Till date all attempts to get drugs into the brain were countered by the blood-brain barrier - the natural defense against potentially harmful chemicals floating around the body. However this new finding from a team from University of Oxford shows that now scientists have successfully switched off a gene implicated in Alzheimer’s disease in the brains of mice by exploiting tiny particles naturally released by cells, called exosomes.

21 Mar 2011

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.

18 Mar 2011

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

17 Mar 2011

Study finds synapses between retinal ganglion cells and starburst amacrine cells distributed asymmetrically

The sensory cells in the retina of the mammalian eye convert light stimuli into electrical signals and transmit them via downstream interneurons to the retinal ganglion cells which, in turn, forward them to the brain. The interneurons are connected to each other in such a way that the individual ganglion cells receive visual information from a circular area of the visual field known as the receptive field.

10 Mar 2011

Summer Street Research announces recent closing of financing for IMUC

Summer Street Research Partners is pleased to announce the recent closing of a financing for ImmunoCellular Therapeutics, Ltd., a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

5 Mar 2011

PDI introduces new division for clinical educators to optimize patient care and outcomes

PDI, Inc. today announced the launch of a new division, EngageCE, that will offer expert clinical educators to work with health care providers in the management of chronic diseases in order to optimize patient care and outcomes.

3 Mar 2011

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Argos Therapeutics announced today that its Arcelis immunotherapy for the treatment of HIV, AGS-004, demonstrated positive outcomes with the primary endpoint of viral load control and a favorable safety and immunogenicity profile in a final analysis of a Phase 2a clinical trial.

3 Mar 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

ImmunoCellular to receive gross proceeds of $8.1M from sale of 5.2M units

ImmunoCellular Therapeutics, Ltd., announced it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing.

24 Feb 2011

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 – 19, 2011.

19 Feb 2011

Scientists discover axons can send signals to cell body

Neurons are complicated, but the basic functional concept is that synapses transmit electrical signals to the dendrites and cell body, and axons carry signals away.

18 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

UCLA researchers amp up power of killer CD8 T-cells to fight melanoma

ImmunoCellular reports updated ICT-107 Phase I trial data in glioblastoma multiforme

Four medical centers enroll additional patients for NWBT's ongoing brain cancer trial

New nano-vault delivery system can fight cancer

ARIAD executes three exclusive out-license agreements for ARGENT cell-signaling regulation technology

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

Positive results from ULCA's Phase 1 dendritic cell vaccine trial in glioblastoma

Research outlines how cilia disease gene products regulate early cilium formation

Drug delivery breakthrough for Alzheimer’s disease

Individualized dentritic cell vaccine may increase survival time in patients with glioblastoma

Personalized dendritic cell vaccine may increase median survival in mesenchymal glioblastoma patients

Study finds synapses between retinal ganglion cells and starburst amacrine cells distributed asymmetrically

Summer Street Research announces recent closing of financing for IMUC

PDI introduces new division for clinical educators to optimize patient care and outcomes

Positive outcomes from Argos AGS-004 Phase 2a trial in patients with HIV

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

ImmunoCellular to receive gross proceeds of $8.1M from sale of 5.2M units

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Scientists discover axons can send signals to cell body

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in